Current practice guidelines advocate culprit vessel intervention alone in patients with ST-segment elevation myocardial infarction (STEMI) found to have multivessel coronary disease during primary percutaneous coronary intervention (PCI).
T imely treatment of the culprit lesion in acute ST-segment elevation myocardial infarction (STEMI) is essential to minimizing myocardial necrosis, curbing recurrent ischemia, and reducing mortality (1) . Primary percutaneous coronary intervention (PCI) is the gold standard for restoration of blood flow in the infarct artery (2) . STEMI patients with multivessel (MV) coronary artery disease (CAD) have higher mortality rates and a higher incidence of recurrent myocardial infarction (MI) than patients with single-vessel CAD, and the presence of triple-vessel CAD diagnosed during MI portends a worse prognosis (3, 4) . Although it can be assumed that the extent of CAD has a direct impact Myocardial Infarction) trial, in which Wald et al. (9) studied PCI in nonculprit coronary lesions at the time of primary PCI for STEMI, a practice they termed "preventive stenting." In contrast to current guidelines and the studies that informed them (10) (11) (12) (13) , the PRAMI investigators demonstrated that in patients undergoing primary PCI for STEMI, the combined rate of cardiac death, nonfatal MI, and refractory angina (defined as angina despite medical therapy supported by objective evidence of ischemia including electrocardiographic changes during a spontaneous episode of pain, a positive stress test result, or pressure-wire assessment) was reduced by 65% in the preventive PCI group, with an absolute risk reduction of 14%, compared with the group that did not undergo additional stenting (9) . However, only 2 strategies were tested: simultaneous, preventive PCI of nonculprit vessel obstructive disease versus culprit vessel revascularization only. There was no arm for nonculprit vessel staged PCI. Taken together, these findings suggest that acute myocardial infarction reflects more generalized pathophysiological derangements of endothelial dysfunction, coagulation, and inflammation, with the potential to impair coronary perfusion beyond the culprit lesion distribution and destabilize plaque throughout the coronary vasculature (5, 26, 27) .
Perhaps the benefit seen in the PRAMI trial reflects the impact of stabilizing such vulnerable plaques with PCI. with an absolute risk reduction of 14% (hazard ratio: 
